Amerise Biosciences Ltd

AGM Details

• AGM held on 24 September 2026 at 3:00 PM at registered office; mode physical with remote e-voting.

Voting outcomes

• Turnout: 19.19% of outstanding shares polled.
• Ordinary resolution for adoption of audited financial statements and reports; passed 100%.
• Ordinary resolution for appointment of Mr. Albert Hines as Wholetime Director and CFO; passed 100%.

AGM details

• Held on 24 September 2026 at 3:00 PM, physical meeting at registered office.
• AGM duration: 3:00 PM to 3:30 PM.

Key resolutions

• Adoption of audited financial statements for year ended 31 March 2026.
• Appointment of Mr. Albert Hines as Whole-time Director and Chief Financial Officer.

Voting results

• Resolutions passed by shareholders at the AGM.

Amerise Biosciences Limited: Trading Window closed from Thursday, 1 October, 2026 till 48 (Forty-Eight) hours after the announcement/declaration of Unaudited Financial Results for the second quarter ended on 30th September 2026.

Transaction details

• Target: Amerise Biosciences Ltd.
• Acquirer and PACs: SNEHJEEV VENTURES PVT.LTD.; Rushank S. Lunkad; Sneha Lunkad; Riddhi Lunkad; Sanjeev Lunkad.
• Promoter group: No.
• Transaction: Acquisition of voting shares.
• Pre-holding: 7,215,959 shares (10.92%).
• Encumbrances before: Nil.
• Shares acquired: 76,725 shares (0.12%).
• Post-holding: 7,292,684 shares (11.04%).
• Mode: Open Market.
• Date: 14-08-2026.
• Equity capital before: Rs 6,60,69,000; shares: 66,06,900.
• Equity capital after: Rs 6,60,69,000; shares: 66,06,900.
• Total diluted capital after: NA.

Standalone results

• Q1 FY27: Revenue from operations 7.92 lacs; net loss after tax 8.14 lacs.
• Q1 FY27: Basic and diluted EPS -0.01.
• FY26: Total income 25.52 lacs; net profit after tax 1.61 lacs; EPS 0.00.
• Paid-up equity share capital 660.69 lacs.

Key filing details

• Target Company: Amerise Biosciences Ltd (AMERISE, 531681).
• Scrip/ID: AMERISE, 531681.
• Filing date: 29.07.2026.
• Disclosing Party: not disclosed in this chunk.
• Transaction Type: not disclosed.
• Pre-Transaction Holding: not disclosed.
• Transaction Details: not disclosed.
• Post-Transaction Holding: not disclosed.
• Date(s) of Transaction: not disclosed.
• Share Capital Context: not disclosed.

Filing summary

• Disclosure submission under Reg. 29(2) by Amerise Biosciences Ltd (Scrip 531681) dated 16 July 2026.

Dematerialisation status

• The dematerialised securities have been listed on the stock exchanges.
• Physical certificates were mutilated and cancelled; depository registered owner name substituted.
• No physical certificates were received for demat in the quarter.